📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

VSN16S, an agonist of the cannabinoid receptor, reduces IOP profiles and exhibits neuroprotective properties in a rat model of glaucoma (2022)

First Author: Guo L

Attributed to: Biomedical Catalyst – Drug product production, clinical support studies, and phase 1 trial of a new MS drug funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/j.1755-3768.2022.116

Publication URI: http://dx.doi.org/10.1111/j.1755-3768.2022.116

Type: Journal Article/Review

Parent Publication: Acta Ophthalmologica

Issue: S267